New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
06:38 EDTVRTXVertex a buy into Phase 3 data for VX-809, says Deutsche Bank
Deutsche Bank said it would be a buyer of Vertex shares into the company's mid-2014 Phase 3 data for VX-809. The firm expects the primary endpoint to be hit and thinks shares could trade to $103-$111 on good data. Deutsche says shares of Vertex could trade down to $30-$35 with a Phase 3 failure. It has a Buy rating on the stock with a $103 price target.
News For VRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 26, 2015
07:09 EDTVRTXVertex, Novavax among select biotechs to buy on weakness, says Piper Jaffray
Subscribe for More Information
August 24, 2015
13:36 EDTVRTXBiotech correction presents some opportunities, says RBC Capital
RBC Capital analyst Michael Yee said he won't try to pick the short-term bottom in biotech, but contends that any macro weakness in China shouldn't have any major impact to financials or fundamentals for the sector given their minimal exposure there. If the market continues to be volatile, Yee recommends a focus on names with defensive characteristics, such as higher margins and free cash flow yield, naming Amgen (AMGN), Celgene (CELG) and Gilead (GILD) as some examples. The analyst adds that he likes Vertex (VRTX) on the pullback for "more aggressive" growth investors. Yee has Outperform ratings on all of the stocks mentioned above.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use